A Retrospective Review of Metastatic or Recurrent Uterine Sarcomas Treated with Ifosfamide and Doxorubicin (IMA)

Aksoy, Sercan; Hizli, Deniz; Sarici, Saynur; Öcalan, Reyhan; Köse, M. Faruk; Güler, Nilüfer
September 2008
International Journal of Hematology & Oncology / UHOD: Uluslarar;Sep2008, Vol. 18 Issue 3, p129
Academic Journal
The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4 to 26 months. We evaluated the efficacy and toxicity of ifosfamide (I), mesna (M) and doxorubicin (A) (IMA) chemotherapy regimen retrospectively in patients with metastatic or recurrent uterine sarcomas. Forty-two patients were enrolled in this study. The median age was 53 years (range, 18-72). Thirty-seven patients were assessable for response and survival; forty patients were assessable for toxicity. A total of 162 cycles of chemotherapy were introduced and for each patient and median number of chemotherapy cycles were 4 (range, 1-6). We observed complete response (CR) in 3 patients; partial response (PR) in 14 patients. Objective RR was 46% (95% CI, 30% to 62%). The median progression-free survival time of the responders was 8.0 months (range, 4-35). The median progression- free survival time of all patients was 5.0 months. Febrile neutropenia was encountered in 6 patients. Dose modifications were required in 4 patients due to myelotoxicity. Central nervous system (CNS) toxicity was observed in three patients. IMA regimen has moderate anti-tumor activity (46%) with acceptable toxicity in patients with recurrent or metastatic uterine sarcomas.


Related Articles

  • Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Nowakowski, G S; LaPlant, B; Habermann, T M; Rivera, C E; Macon, W R; Inwards, D J; Micallef, I N; Johnston, P B; Porrata, L F; Ansell, S M; Klebig, R R; Reeder, C B; Witzig, T E // Leukemia (08876924);Dec2011, Vol. 25 Issue 12, p1877 

    Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish the maximum tolerated dose of lenalidomide that could be combined with R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and...

  • Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Campos, Susana M.; Berlin, Suzanne T.; Parker, Leroy M.; Chen, Wendy Y.; Bunnell, Craig A.; Atkinson, Tina; Lee, Julie; Matulonis, Ursula; Hirsch, Michelle S.; Harris, Lyndsay; Krasner, Carolyn N. // International Journal of Clinical Oncology;Aug2010, Vol. 15 Issue 4, p390 

    Pegylated liposomal doxorubicin has activity in both breast and ovarian cancer. Preclinical data noted that ZD1839 acts synergistically with chemotherapy. Given the lack of cross-resistance between these two agents, a phase I trial was initiated examining the safety and efficacy of the...

  • A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Bozionelou, V.; Vamvakas, L.; Pappas, P.; Agelaki, S.; Androulakis, N.; Kalykaki, A.; Nikolaidou, M.; Kentepozidis, N.; Giassas, S.; Marselos, M.; Georgoulias, V.; Mavroudis, D. // British Journal of Cancer;7/2/2007, Vol. 97 Issue 1, p43 

    To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two patients with advanced-stage solid tumours...

  • Neutropenia: State of the Knowledge Part I. Nirenberg, Anita; Bush, Annette Parry; Davis, Arlene; Friese, Christopher R.; Gillespie, Theresa Wicklin; Rice, Robert David // Oncology Nursing Forum;Nov2006, Vol. 33 Issue 6, p1193 

    Purpose/Objectives: To review neutrophil physiology, consequences of chemotherapy-induced neutropenia (CIN), CIN risk assessment models, national practice guidelines, the impact of febrile neutropenia and infection, and what is known and unknown about CIN. Data Sources: Extensive review and...

  • A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas. Anderson, Sibyl E.; Keohan, Mary L.; D'Adamo, David R.; Maki, Robert G. // Sarcoma;2006, Vol. 2006, p1 

    The role of vinorelbine in specific soft tissue sarcoma subtypes is unclear. We present retrospective single institution experience with single-agent vinorelbine in subjects with metastatic soft tissue malignancies. Methods. Fifty-eight patients were treated with single agent intravenous...

  • Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention. Pai, V.B.; Nahata, M.C. // Drug Safety;Apr2000, Vol. 22 Issue 4, p263 

    Cytostatic antibiotics of the anthracycline class are the best known of the chemotherapeutic agents that cause cardiotoxicity. Alkylating agents such as cyclophosphamide, ifosfamide, cisplatin, carmustine, busulfan, chlormethine and mitomycin have also been associated with cardiotoxicity. Other...

  • New Trends in Patient Management: Risk-Based Therapy for Febrile Patients with Neutropenia. Rolston, Kenneth V.I. // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p515 

    Presents the traditional therapy for febrile neutropenia. Concepts of risk-assessment and risk-based therapy for the various subsets of febrile patients with neutropenia; Details of varying methods of therapy based on the level of risk of patients with febrile neutropenia; Summary of the...

  • Pegfilgrastim for Chemotherapy-Induced Neutropenia. Bedell, Cindi // Clinical Journal of Oncology Nursing;Jan/Feb2003, Vol. 7 Issue 1, p55 

    Many chemotherapy regimens cause myelosuppression, which can result in febrile neutropenia and potentially lead to serious infections. The risk of neutropenia and its complications can be reduced with filgrastim, a granulocyteu colony-stimulating factor. Filgrastim is safe and effective, but it...

  • ABV "most rational" option for Kaposi's sarcoma in Brazil.  // PharmacoEconomics & Outcomes News;12/16/2006, Issue 518, p5 

    The article presents information on a study on the cost-effectiveness of a chemotherapy regimen of doxorubicin, bleomycin plus vincristine (ABV) in the treatment of AIDS-related Kaposi's sarcoma in Brazil conducted by T. M. Vanni, C. A. Polanczyk et al, published in the July-August 2006 issue of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics